Monitoring clone dynamics and reversibility in clonal haematopoiesis and myelodysplastic neoplasm associated with PARP inhibitor therapy-a role for early monitoring and intervention

Leukemia. 2024 Jan;38(1):215-218. doi: 10.1038/s41375-023-02040-6. Epub 2023 Nov 17.

Authors

Ellen Nuttall Musson¹, Rowan E Miller², Marc R Mansour^{3

2}, Michelle Lockley^{2

4}, Jonathan A Ledermann^{3

2}, Elspeth M Payne^{3

2}

Affiliations

¹ UCL Cancer Institute, London, UK. e.musson@ucl.ac.uk.
² University College London Hospitals NHS Foundation Trust, London, UK.
³ UCL Cancer Institute, London, UK.
⁴ Centre for Cancer Genomics and Computational Biology, Barts Cancer Institute, Queen Mary University of London, London, UK.

No abstract available

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Clonal Hematopoiesis
Clone Cells
Hematopoiesis / genetics
Humans
Myelodysplastic Syndromes* / drug therapy
Myelodysplastic Syndromes* / genetics
Neoplasms*
Poly(ADP-ribose) Polymerase Inhibitors / therapeutic use

Substances

Poly(ADP-ribose) Polymerase Inhibitors

Grants and funding